This antibody detects Trag 3. Weakly expressed in kidney. Expressed in various tumor cell lines including carcinomas, myeloid and lymphoid malignancies, melanomas and prostate cancer. Overexpressed in taxol-resistant breast cancer line MDA 435(TR) and the doxorubicin-resistant multiple myelanoma lines 8226/Dox(40).
Aufreinigung
Purified
Immunogen
Synthetic peptide derived from the human Trag-3 protein
CSAG1 antikoerper, CSAG3B antikoerper, CSAG3 antikoerper, CT24.2 antikoerper, TRAG-3 antikoerper, TRAG3 antikoerper, chondrosarcoma-associated gene 2/3 protein antikoerper, CSAG family member 2 antikoerper, LOC705860 antikoerper, LOC738247 antikoerper, CSAG2 antikoerper
Hintergrund
The expression of the cancer-testis antigen Taxol resistance-associated gene-3 (TRAG-3) is associated with acquired paclitaxel (Taxol) resistance, and is expressed in a variety of cancers - e.g., breast cancer, leukemia, and melanoma. Overexpressed in taxol-resistant breast cancer line MDA 435(TR) and the doxorubicin-resistant multiple myelanoma lines 8226/Dox(40) and 8226/MDR(10)V. Weakly expressed in kidney. TRAG-3 is an attractive target for immunotherapy of cancer. First identified as a novel cancer/testis antigen, TRAG-3, (Taxol Resistance Associated Gene-3) was initially discovered in a search for new genes involved in drug resistance. Early studies of TRAG-3 revealed a minimal to absent expression in normal tissues and a marked over-expression in many carcinoma cell lines including several melanoma lines. By RT-PCR evaluation of TRAG-3 two transcripts are seen in many carcinoma cell lines with products in the the 799 bp and a second alternatively spliced transcript.Synonyms: CT24.2, Cancer/testis antigen 24.2, Chondrosarcoma-associated gene 2/3 protein, TRAG-3, TRAG3, Taxol-resistant-associated gene 3 protein